Abstract
INTRODUCTION AND IMPORTANCE: Progress in the management of pancreas cancer has been slow to occur. Resection of the primary cancer in the head of the pancreas is possible and has become a standard of care in operable patients. Unfortunately, long-term survival after this extensive surgical procedure is nearly nonexistent. CASE PRESENTATION: A 55-year-old man was diagnosed with cancer within the pancreas head. He underwent a successful pancreaticoduodenectomy. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with gemcitabine was added in an attempt to eliminate cancer cells present within the peritoneal space at the time of the resection. Also, six cycles of normothermic intraperitoneal chemotherapy (NIPEC) delivered through an intraperitoneal port were completed. The patient developed a solitary liver metastasis which was removed with adequate margins. The patient remains alive and well and working ten years following treatments. CLINICAL DISCUSSION: Pancreas cancer shows treatment failures on peritoneal surfaces, as liver metastases, and as systemic and distant lymph nodal disease. The pharmacology of intraperitoneal gemcitabine suggests that it can eliminate peritoneal metastases as a site for treatment failure. Radical surgery can remove lymph nodes in and around the malignancy that are likely to cause a recurrence. Eliminating other sites of treatment failure in this patient allowed the liver resection to result in a long-term survival. CONCLUSIONS: In patients with resectable cancer of the head of the pancreas, local-regional and distant peritoneal recurrence may be reduced as a result of HIPEC and NIPEC gemcitabine being added to the treatments. Additional chemotherapy agents are available to supplement the intraoperative and long-term intraperitoneal gemcitabine treatments. A strategy for bidirectional (both intravenous and intraperitoneal) chemotherapy for pancreas cancer remains as a viable option for improved survival.